Peri-operative SLOG for Localized Pancreatic Cancer

Inclusion Criteria: A. Localized resectable or potentially resectable pancreatic cancer as determined by image modality; resectability is determined by the treating surgeon No prior treatment for pancreatic cancer B. Patients must agree to receive biopsy for histological diagnosis and provide residual tissue for biomarker analysis before chemotherapy C. Patients must agree to provide tissue for biomarker analysis after neoadjuvant chemotherapy, either surgical specimen or follow-up biopsy in unsectable disease D. At least one measurable lesion according to RECIST version 1.1 E. Ability to understand and willingness to sign a written informed consent document. F. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 G. Age of 20 years or above H. Life expectancy of at least 12 weeks I. Adequate organ function as defined by the following criteria: * absolute neutrophil count (ANC) ≥ 1,500/mm3 * hemoglobin level ≥ 9 g/dL * platelet count ≥ 100,000/mm3 * total bilirubin \< 2 mg/dL * aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) * creatinine clearance rate (CCr) ≥ 50 mL/min (24-hour urine collection or calculated by Cockroft-Gault formula; male: \[(140 - age) × weight (kg)\]/\[72 × serum creatinine(mg/dL)\];female=male x 0.85 J. Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study. Exclusion Criteria: A. Other malignancy with…